Journal of Surgery Concepts & Practice ›› 2018, Vol. 23 ›› Issue (05): 385-389.doi: 10.16139/j.1007-9610.2018.05.001
• Editorial • Next Articles
Received:2018-08-29
Online:2018-09-25
Published:2020-07-25
CLC Number:
| [1] Grady WM, Carethers JM.Genomic and epigenetic instability in colorectal cancer pathogenesis[J]. Gastroentero-logy,2008,135(4):1079-1099. [2] Laurent-Puig P, Agostini J, Maley K.Colorectal oncogenesis[J]. Bull Cancer,2010,97(11):1311-1321. [3] Walther A, Houlston R, Tomlinson I.Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis[J]. Gut,2008,57(7):941-950. [4] Juo YY, Johnston FM, Zhang DY, et al.Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis[J]. Ann Oncol,2014,25(12):2314-2327. [5] Overman MJ, Lonardi S, Wong KYM, et al.Durable cli-nical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol,2018,36(8):773-779. [6] Kopetz S, Mcdonough SL, Morris VK, et al.Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406)[J]. J Clin Oncol,2017,35(4 suppl):520. [7] Cancer Genome Atlas N. Comprehensive molecular chara-cterization of human colon and rectal cancer[J]. Nature,2012,487(7407):330-337. [8] Schlicker A, Beran G, Chresta CM, et al.Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines[J]. BMC Med Genomics,2012,5:66. [9] Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value[J]. PLoS Med,2013,10(5):e1001453. [10] Sadanandam A, Lyssiotis CA, Homicsko K, et al.A colo-rectal cancer classification system that associates cellular phenotype and responses to therapy[J]. Nat Med,2013, 19(5):619-625. [11] De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions[J]. Nat Med,2013,19(5):614-618. [12] Budinska E, Popovici V, Tejpar S, et al.Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer[J]. J Pathol,2013,231(1):63-76. [13] Roepman P, Schlicker A, Tabernero J, et al.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition[J]. Int J Cancer,2014,134(3):552-562. [14] Muller MF, Ibrahim AE, Arends MJ.Molecular patholo-gical classification of colorectal cancer[J]. Virchows Arch,2016,469(2):125-134. [15] Lee GH, Malietzis G, Askari A, et al.Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review[J]. Eur J Surg Oncol,2015,41(3):300-308. [16] Price TJ, Beeke C, Ullah S, et al.Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?[J]. Cancer,2015,121(6):830-835. [17] Cheng L, Eng C, Nieman LZ, et al.Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005[J]. Am J Clin Oncol,2011,34(6):573-580. [18] Benedix F, Kube R, Meyer F, et al.Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histo-logy, and survival[J]. Dis Colon Rectum,2010,53(1):57-64. [19] Meguid RA, Slidell MB, Wolfgang CL, et al.Is there a difference in survival between right- versus left-sided colon cancers?[J]. Ann Surg Oncol,2008,15(9):2388-2394. [20] Snaebjornsson P, Jonasson L, Jonsson T, et al.Colon cancer in Iceland--a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age[J]. Int J Cancer,2010,127(11):2645-2653. [21] Bettington M, Walker N, Clouston A, et al.The serrated pathway to colorectal carcinoma: current concepts and challenges[J]. Histopathology,2013,62(3):367-386. [22] Fischer von Weikersthal L, Schalhorn A, Stauch M, et al. Phase Ⅲ trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer[J]. Eur J Cancer,2011,47(2):206-214. [23] Venook A, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase Ⅲ trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)[J]. J Clin Oncol,2014,32(suppl 15):LBA 3. [24] Weiss JM, Pfau PR, O′Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data[J]. J Clin Oncol,2011,29(33):4401-4409. [25] Niida A, Nagayama S, Miyano S, et al.Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling[J]. Cancer Sci,2018,109(4):884-892. [26] Lee SY, Haq F, Kim D, et al.Comparative genomic analy-sis of primary and synchronous metastatic colorectal cancers[J]. PLoS One,2014,9(3):e90459. [27] Knösel T, Schluns K, Stein U, et al.Chromosomal altera-tions during lymphatic and liver metastasis formation of colorectal cancer[J]. Neoplasia,2004,6(1):23-28. [28] Luo D, Liu Q, Yu W, et al. Prognostic value of distant metastasis sites and surgery in stage Ⅳ colorectal cancer: a population-based study[J]. Int J Colorectal Dis,2018-06-21 [Epub ahead of print]. [29] Kim JH, Kang GH.Molecular and prognostic heterogenei-ty of microsatellite-unstable colorectal cancer[J]. World J Gastroenterol,2014,20(15):4230-4243. [30] Yan Y, Lackner MR.FOXO3a and beta-catenin co-locali-zation: double trouble in colon cancer?[J]. Nat Med,2012,18(6):854-856. [31] Ozawa T, Kandimalla R, Gao F, et al.A microRNA signature associated with metastasis of T1 colorectal cancers to lymph nodes[J]. Gastroenterology,2018,154(4):844-848. [32] Li Y, Jia H, Yu W, et al.Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection[J]. Int J Cancer,2016,139(1):220-231. [33] Li Y, Liang L, Dai W, et al.Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer[J]. Mol Cancer,2016,15(1):55. [34] Li Q, Wu J, Wei P, et al.Overexpression of forkhead box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition[J]. Am J Cancer Res,2015,5(6):2022-2034. [35] Li Q, Wei P, Huang B, et al.MAEL expression links epithelial-mesenchymal transition and stem cell properties in colorectal cancer[J]. Int J Cancer,2016,139(11):2502-2511. [36] Li Q, Qin Y, Wei P, et al.Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma[J]. Mol Cancer Res,2016,14(9):830-840. [37] Li Q, Wei P, Wu J, et al. The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhan-cing the Warburg effect[J]. Oncogene,2018-08-31. [38] Adua D, Di Fabio F, Ercolani G, et al.Heterogeneity in the colorectal primary tumor and the synchronous resec-ted liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody[J]. Mol Clin Oncol,2017, 7(1):113-120. [39] Touil Y, Igoudjil W, Corvaisier M, et al.Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis[J]. Clin Cancer Res,2014,20(4):837-846. [40] Yang P, Yang Y, An W, et al.The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway[J]. J Gastroenterol Hepatol,2017,32(4):837-845. |
| [1] | LIU Haishan, CAI Zhenghao, MA Junjun, SUN Jing, HE Zirui, ZANG Lu, DONG Feng, FENG Bo, ZONG Yaping, XUE Pei, ZHANG Luyang, LU Aiguo, ZHENG Minhua. A retrospective study on laparoscopic complete mesocolic excision via dorsal-medial hybrid approach for right colon cancer [J]. Journal of Surgery Concepts & Practice, 2020, 25(03): 211-216. |
| [2] | . [J]. Journal of Surgery Concepts & Practice, 2019, 24(06): 546-549. |
| [3] | . [J]. Journal of Surgery Concepts & Practice, 2019, 24(05): 470-474. |
| [4] | . [J]. Journal of Surgery Concepts & Practice, 2019, 24(04): 367-370. |
| [5] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 390-393. |
| [6] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 394-397. |
| [7] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 398-401. |
| [8] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 405-408. |
| [9] | JIANG Yimei, LIU Kun, SHI Yiqin, SONG Zijia, LI You, ZHAO Ren. Single-port and three-port laparoscopic radical resection in colorectal cancer： a retrospective study [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 418-424. |
| [10] | LIU Kun, LUO Fangxiu, FANG Xuqian, SHI Yiqing, JIANG Yimei, CHEN Peizhan, ZHAO Ren. Relationship between Cortactin expression level and tumor budding in colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 425-429. |
| [11] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 456-458. |
| [12] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 462-465. |
| [13] | ZHOU Yong, CUI Rong, SHI Xingyao. Analysis of long non-coding RNA TUG1 expression in colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2018, 23(04): 374-378. |
| [14] | YU Minhao, QI Yang, QIN Shaolan, MU Yifei, LUO Yang, QIU Yier, CUI Ran, ZHONG Ming. A retrospective controlled clinical study on laparoscopic versus open complete mesocolic excision for right colon cancer [J]. Journal of Surgery Concepts & Practice, 2018, 23(02): 145-149. |
| [15] | . [J]. Journal of Surgery Concepts & Practice, 2018, 23(01): 84-86. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
